Welcome to our dedicated page for Artelo Biosciences news (Ticker: ARTL), a resource for investors and traders seeking the latest updates and insights on Artelo Biosciences stock.
Artelo Biosciences, Inc. (NASDAQ: ARTL) is a clinical-stage biopharmaceutical company headquartered in San Diego, California, with an additional office in Dublin, Ireland. The company is dedicated to the development and commercialization of proprietary therapeutics that modulate lipid signaling pathways, including the endocannabinoid system. Artelo leverages past research and cutting-edge science to accelerate the development of a diverse portfolio of novel therapeutics with the potential to dramatically improve patient care in major markets.
Core to Artelo's mission is their focus on discovering, licensing, developing, and commercializing treatments that control endocannabinoid systems. This includes cannabinoid-based therapies, both derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The company's flagship program is a patent-protected cannabinoid drug combination treatment aimed at rare and orphan diseases.
One of their notable projects, ART12.11, has demonstrated improved bioavailability of CBD in both fed and fasted states compared to CBD alone. This proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP) offers biopharmaceutic advantages over standard CBD compositions, showing better pharmacokinetics and improved efficacy in preclinical studies. The US-issued composition of matter patent for ART12.11 is enforceable until December 10, 2038.
Another significant program is ART26.12, a Fatty Acid Binding Protein 5 (FABP5) inhibitor being developed as a non-opioid, non-steroidal analgesic for chemotherapy-induced peripheral neuropathy (CIPN) and potentially other neuropathic pains. ART26.12 has shown promising results in preclinical studies, reducing pain in models of diabetic neuropathy and chemotherapy-induced peripheral neuropathy.
Artelo is also advancing ART27.13, a G-Protein Coupled Receptor (GPCR) agonist targeting CB1 and CB2 receptors. This program is currently in the Cancer Appetite Recovery Study (CAReS) Phase 2a trial, aimed at improving body weight, appetite, muscle degeneration, and quality of life in cancer patients. The company has reported positive progress in clinical trials and aims to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, pain, neuropathy, and inflammation.
Led by experienced biopharmaceutical executives and backed by collaborations with highly respected researchers and technology experts, Artelo applies rigorous scientific, regulatory, and commercial discipline to develop high-impact therapies. The company maintains a strong presence in global biopharma innovation hubs, ensuring close access to world-class research expertise.
Artelo Biosciences (Nasdaq: ARTL) has initiated the Phase 2a segment of its Cancer Appetite Recovery Study (CAReS) for ART27.13, aimed at treating cancer-related anorexia and weight loss. The study will assess 40 patients, using a 3:1 ratio for ART27.13 versus placebo over 12 weeks. Following positive safety outcomes in Phase 1b, a dose of 650 micrograms will be administered. About 18 clinical sites across five countries will participate. ART27.13 targets cannabinoid receptors and has shown potential for increasing appetite without adverse central nervous system effects. The global market for addressing anorexia in cancer patients is estimated over $2 billion. The company hopes to complete patient enrollment by mid-2024.
Artelo Biosciences (Nasdaq: ARTL) reported significant developments for the fiscal year ending December 31, 2022, highlighting $17.5 million in cash and marketable securities available to support operations into the latter half of 2024. The CEO emphasized advances in their clinical trial for ART27.13, aimed at treating cancer-related anorexia, with enrollment completion of all cohorts and the next Phase 2a stage anticipated to start in April 2023. The company also noted a net loss of $10.1 million for the year and a strategic full pipeline development, including research on their lead fatty acid binding protein inhibitor.
Artelo Biosciences (NASDAQ:ARTL), a clinical-stage pharmaceutical company, will present at the MicroCap Rodeo's Third Annual Winter Wonderland Best Ideas Virtual Investor Conference from February 21-24, 2023. CEO Gregory D. Gorgas is scheduled to present on February 22 at 9:00 a.m. Eastern Time, with a live webcast available for replay. The conference highlights 37 companies recommended by qualified institutional investors, showcasing top investment ideas. Artelo is focused on developing therapies for conditions including cancer, pain, and neurological disorders. For more details or to schedule meetings, interested parties can contact the company.
Artelo Biosciences (ARTL) has completed enrollment in the final cohort of its Phase 1b Cancer Appetite Recovery Study (CAReS) for ART27.13, aimed at evaluating safety and efficacy in cancer patients experiencing anorexia. The highest permissible dose of 650 micrograms has been administered, with preliminary results indicating a well-tolerated safety profile and mild adverse reactions. The company anticipates progressing to the randomized Phase 2a stage to assess the drug's effectiveness, targeting a market projected to exceed $2 billion for cancer-related appetite loss treatments. Artelo expresses gratitude to participants and research teams for overcoming enrollment challenges.
Artelo Biosciences, a clinical-stage pharmaceutical company, announced that CEO Gregory D. Gorgas will present at the Sequire Biotechnology Conference on February 2, 2023, at 1:00 PM ET. The presentation will focus on the Company’s ongoing Cancer Appetite Recovery Study (CAReS). The biotechnology sector is projected to reach $727 billion by 2025, highlighting its growth potential. This event, hosted virtually, aims to connect public biotech companies with investors. Artelo is dedicated to developing innovative treatments targeting significant unmet needs related to cancer and other conditions. More details can be found at artelobio.com.
Artelo Biosciences (Nasdaq: ARTL) reported financial results for the quarter ending September 30, 2022, showing a net loss of approximately $2.3 million, or $0.82 per share, compared to a loss of $2.2 million or $1.37 per share for the same period in 2021. As of September 30, 2022, the company had $19.5 million in cash and investments, expected to support operations through mid-2024. Enrollment for the Phase 2a Cancer Appetite Recovery Study (CAReS) is set to begin near year-end, following positive Phase 1b results.
Artelo also highlighted promising non-clinical data for its FABP5 platform, indicating potential treatments for both pain and anxiety.
Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company, will present at the 2022 Ladenburg Thalmann Healthcare Conference on September 29, 2022, in New York City. CEO Gregory D. Gorgas will speak at 8:30 a.m. ET, and one-on-one meetings will be available throughout the event. The presentation will also be streamed online. Artelo focuses on developing treatments for cancer, pain, and neurological conditions through lipid-signaling pathways, aiming to address significant unmet medical needs.
Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company, announced that CEO Gregory D. Gorgas will present at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The event includes virtual and in-person attendance at the Lotte New York Palace Hotel. The presentation will be available on-demand starting September 12 at 7:00 AM ET. Artelo focuses on developing treatments for cancer, pain, and neurological conditions through lipid-signaling pathway modulation.
Artelo Biosciences (ARTL) recently announced pre-clinical findings suggesting that its fatty acid binding protein 5 (FABP5) inhibitor may effectively reduce anxiety behaviors in key brain areas. These results indicate that FABP5 modulation could serve as a new target for developing anxiety treatments, including potential therapies for post-traumatic stress disorder (PTSD). Published in Cerebral Cortex, the study led by researchers from the University of Western Ontario demonstrates the role of the CB2 receptor in managing fear and anxiety, underscoring the importance of this research.
FAQ
What is the current stock price of Artelo Biosciences (ARTL)?
What is the market cap of Artelo Biosciences (ARTL)?
What does Artelo Biosciences do?
Where is Artelo Biosciences headquartered?
What are the main therapeutic areas Artelo Biosciences focuses on?
What is ART12.11?
What is ART26.12?
What is ART27.13?
What recent achievement has ART12.11 demonstrated?
What progress has been made in the ART26.12 program?
Who leads Artelo Biosciences?
Where can I find more information about Artelo Biosciences?
